Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Pharming Group stock price, quote, forecast and news

PHARM.AS
NL0010391025
A1H65A

Price

0.73
Today +/-
-0.03
Today %
-4.20 %
P

Pharming Group stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Pharming Group stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Pharming Group stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Pharming Group stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Pharming Group's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Pharming Group Stock Price History

DatePharming Group Price
9/6/20240.73 undefined
9/5/20240.76 undefined
9/4/20240.76 undefined
9/3/20240.75 undefined
9/2/20240.78 undefined
8/30/20240.78 undefined
8/29/20240.79 undefined
8/28/20240.78 undefined
8/27/20240.79 undefined
8/26/20240.80 undefined
8/23/20240.81 undefined
8/22/20240.81 undefined
8/21/20240.81 undefined
8/20/20240.80 undefined
8/19/20240.82 undefined
8/16/20240.81 undefined
8/15/20240.80 undefined
8/14/20240.79 undefined
8/13/20240.77 undefined
8/12/20240.78 undefined

Pharming Group Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Pharming Group, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Pharming Group from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Pharming Group’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Pharming Group. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Pharming Group’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Pharming Group’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Pharming Group’s growth potential.

Pharming Group Revenue, EBIT and net profit per share

DatePharming Group RevenuePharming Group EBITPharming Group Net Income
2028e432.59 M undefined42.67 M undefined86.57 M undefined
2027e445.25 M undefined20.39 M undefined57.99 M undefined
2026e408.23 M undefined62.49 M undefined40.87 M undefined
2025e345.59 M undefined23.22 M undefined12.23 M undefined
2024e305.92 M undefined985,195 undefined-4.19 M undefined
2023245.32 M undefined-21.75 M undefined-10.55 M undefined
2022205.62 M undefined10.37 M undefined13.67 M undefined
2021198.87 M undefined24 M undefined16 M undefined
2020212.17 M undefined76.26 M undefined37.75 M undefined
2019179.25 M undefined64.59 M undefined38.38 M undefined
2018143.31 M undefined40.29 M undefined26.51 M undefined
201795.04 M undefined23.24 M undefined-80.86 M undefined
201615.81 M undefined-11.5 M undefined-17.47 M undefined
201510.83 M undefined-12.83 M undefined-9.96 M undefined
201421.19 M undefined3.46 M undefined-5.77 M undefined
20136.8 M undefined-6.3 M undefined-15.1 M undefined
201210.6 M undefined-13.1 M undefined-24.1 M undefined
20113 M undefined-16.7 M undefined-17.1 M undefined
20101.7 M undefined-23.4 M undefined-50.2 M undefined
20091.1 M undefined-27.6 M undefined-32.1 M undefined
2008700,000 undefined-25.3 M undefined-26.2 M undefined
2007700,000 undefined-24.3 M undefined-35.6 M undefined
2006100,000 undefined-17.6 M undefined-18.5 M undefined
2005400,000 undefined-18.4 M undefined-17.9 M undefined
2004700,000 undefined-13.4 M undefined-13 M undefined

Pharming Group Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
19961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e
25812189200000011310621101595143179212198205245305345408445432
-150.0060.0050.0050.00-50.00-77.78--------200.00233.33-40.00250.00-52.3850.00533.3350.5325.1718.44-6.603.5419.5124.4913.1118.269.07-2.92
--50.0050.0038.89-22.2250.00--------33.3390.00100.0085.7160.0073.3385.2683.2287.1588.6889.3991.7189.80-----
00467-21-2-4-4-40000196186118111915618817718822000000
-4-6-10-14-15-25-5-10-13-18-17-24-25-27-23-16-13-63-12-11234064762410-21023622042
-200.00-120.00-125.00-116.67-83.33-277.78-250.00-------2,700.00-2,300.00-533.33-130.00-100.0014.29-120.00-73.3324.2127.9735.7535.8512.124.88-8.57-6.6715.204.499.72
-4-5-17-12-22-540-11-13-17-18-35-26-32-50-17-24-15-5-9-17-802638371513-10-412405786
-25.00240.00-29.4183.33145.45--18.1830.775.8894.44-25.7123.0856.25-66.0041.18-37.50-66.6780.0088.89370.59-132.5046.15-2.63-59.46-13.33-176.92-60.00-400.00233.3342.5050.88
1.31.31.31.31.41.41.93.35.988.79.29.211.726.847.473.5214.6396.1411.75415.38500.41653.53673.52682.74701.15707.14657.0200000
---------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Pharming Group Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Pharming Group is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
1996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                       
8.212.871.352.744.91.20.52.725.820.331.154.923.415.910.33.85.31734.1931.6431.7762.2185.1774.35205.16191.92207.34213.42
0.81.52.22.23.300.6000000090.400.20.72.116.269.4316.2628.8623.5118.0820.9635.41
00000.4000.20000000.80.400.40.710.895.091.370.7108.379.524.377.21
0.20.20.100.302.93.12.53.99.211.71111.396.62.14.813.416.2317.8719.4418.3616.2221.1627.3142.3356.76
1.514.16.45.594.20.50.60.80.710.91.10.90.120.72.20.140.230.971.141.9205.012.622.53.54
10.715.577.761.354.410.28.26.528.9254177.535.528.129.213.28.124.649.1451.0961.9593.59122.42119.44263.21249.44277.5316.34
1.848.71926.87.65.84.45.15.58.28.25.978.311.17.16.25.65.666.028.738.9116.321.6533.1739.1533.47
0.20.10.104.10.30.60.50.10.20.20.2000000000006.187.128.659.7310.4
00000000000000000000000009.524.370
1.72.22.62.713.44.91.81.54.33.919.81919.719.419.72.80.50.40.780.7256.4660.0655.6179.494.0883.8375.1271.27
00000.310.10009.29.274.300000000000000
00000000-0.9-0.5-0.7-0.9-1.4-3.4-20-2.40.70.20.20.21.8613.8640.5234.6132.3922.2224.331.38
3.76.311.421.744.613.88.36.48.69.136.735.731.227.3811.58.36.86.586.5964.3582.65105.03136.48155.24157.39152.67146.51
14.421.889.183992416.512.937.534.177.7113.266.755.437.224.716.431.455.7257.68126.3176.24227.46255.92418.45406.84430.17462.85
                                                       
26.814.629.931.733.233.315.819.537.940.244.445.648.777.317.520.410.13.34.084.124.546.146.597.237.317.437.517.67
3.311.380.277.881.683114.1116.1141.5148.5175.3182.2184187.7219.2224.5231.9254.9282.26283.4300.73385.83410.97441.95447.13455.25462.3478.43
-19.8-10-27.4-39.7-62.4-116.5-118.1-128.6-142.1-161.2-179.7-215.3-227.6-262.1-241.2-258.4-249.6-253.2-256.49-263.68-277.91-374.89-352.07-331.79-271.01-269.77-265.17-267.32
00000-0.5-0.6-1.3-1.31.71107.410.415.412.3000000000000
000000000-0.4-1.222.10000000000000000
10.315.982.769.852.4-0.711.25.73628.849.834.612.513.310.9-1.2-7.6529.8423.8427.3617.0865.49117.39183.44192.92204.64218.78
0.62.52.75.658.110.40.63.73.32.82.55.12.921.142.941.025.63107.0440.6547.057.638.7516.02
0.40.51.50.52.32.50.60000000000000.190.2202.2700.6234.8445.7156.51
0.10.20.50.700.100.80.81.94.310.59.97.96.74.96.98.111.38.9619.0430.3940.6420.325.18000
00002.71.91.400000023.200000000000000
0.50.50.4411.65.525.6001.610.30.10.10.11.20.90.80.633.3126.324.0337.6553.3144.35.235.44
1.63.75.110.821.618.156.81.45.69.223.612.536.39.78.18.912.914.8713.4851.1864.4287.6114.2576.8546.7759.777.97
2.52.21.62.325.16.80.30.20.20.1652.538.120.22.221.20.9712.5640.8463.1539.74.89157.96157.46161.46166.11
00000000003.93.63.94.300000000000000
000000000010.100017.315.513.612.310.047.816.9231.5934.6819.380.210.1700
2.52.21.62.325.16.80.30.20.20.12056.1426.317.517.715.613.51120.3647.7694.7474.3824.27158.17157.63161.46166.11
4.15.96.713.146.724.95.371.65.729.279.754.542.627.225.824.526.425.8833.8498.94159.16161.97138.53235.02204.4221.16244.07
14.421.889.482.999.124.216.512.737.634.579114.36755.938.124.616.931.455.7257.68126.3176.24227.46255.92418.45397.32425.8462.85
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Pharming Group provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Pharming Group's financial health and stability.

Assets

Pharming Group's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Pharming Group must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Pharming Group after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Pharming Group's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0000000000000000000-12-11234049442314-12
0000000000000000000003658191315
0000000000000000000000000000
-5-4-18-7-14-3-7-5-10-12-18-21-21-24-3-16-10-8-2-7-110-7-3-5-4-1-14
0000000000-100000000222319370-4-6
00000000000000000000081182434
0000000000000000000000152010
-5-4-18-7-14-3-7-5-10-12-19-21-21-24-3-16-10-8-2-17-9404270833722-17
-2-2-6-11-22-1400-10-30000-10000-1-3-2-24-15-16-1-1
-2-2-6-11-33-1730-1-3-30040-10000-57-6-3-26-15-215-129
0000-11-2300-20004000000-56-2-1-20-47-127
0000000000000000000000000000
100035-22-1200056-18-6-4000015631-18-3583-3-3-5
10118404044348221091813512190871122428
111183040-22373483457-18212121121181567-3-19-6060-27-4-1
000000000011000-107900-5-11-11-27-25-29-3-4
0000000000000000000000000000
3458-18-7-430222-71135-41-178-511215-202922-14130-1315-145
-8.57-7.11-24.77-19.33-36.55-18.29-7.57-5.42-11.41-13.78-22.77-22.4-22.2-24.58-4.07-17.99-10.88-8.31-2.72-18-11.1537.0840.1746.4468.3321.1320.48-18.99
0000000000000000000000000000

Pharming Group stock margins

The Pharming Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Pharming Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Pharming Group.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Pharming Group's sales revenue. A higher gross margin percentage indicates that the Pharming Group retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Pharming Group's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Pharming Group's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Pharming Group's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Pharming Group. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Pharming Group's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Pharming Group Margin History

Pharming Group Gross marginPharming Group Profit marginPharming Group EBIT marginPharming Group Profit margin
2028e89.72 %9.86 %20.01 %
2027e89.72 %4.58 %13.02 %
2026e89.72 %15.31 %10.01 %
2025e89.72 %6.72 %3.54 %
2024e89.72 %0.32 %-1.37 %
202389.72 %-8.87 %-4.3 %
202291.46 %5.04 %6.65 %
202189.37 %12.07 %8.04 %
202088.91 %35.94 %17.79 %
201987.37 %36.03 %21.41 %
201883.59 %28.12 %18.5 %
201786.11 %24.45 %-85.08 %
201670.5 %-72.7 %-110.48 %
201555.67 %-118.53 %-91.96 %
201486.53 %16.31 %-27.22 %
201392.65 %-92.65 %-222.06 %
201289.62 %-123.58 %-227.36 %
201140 %-556.67 %-570 %
201089.72 %-1,376.47 %-2,952.94 %
200989.72 %-2,509.09 %-2,918.18 %
200889.72 %-3,614.29 %-3,742.86 %
200789.72 %-3,471.43 %-5,085.71 %
2006-4,600 %-17,600 %-18,500 %
2005-1,200 %-4,600 %-4,475 %
2004-614.29 %-1,914.29 %-1,857.14 %

Pharming Group Stock Sales Revenue, EBIT, Earnings per Share

The Pharming Group earnings per share therefore indicates how much revenue Pharming Group has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Pharming Group earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Pharming Group's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Pharming Group’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Pharming Group's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Pharming Group Revenue, EBIT and net profit per share

DatePharming Group Sales per SharePharming Group EBIT per sharePharming Group Earnings per Share
2028e0.64 undefined0 undefined0.13 undefined
2027e0.66 undefined0 undefined0.09 undefined
2026e0.6 undefined0 undefined0.06 undefined
2025e0.51 undefined0 undefined0.02 undefined
2024e0.45 undefined0 undefined-0.01 undefined
20230.37 undefined-0.03 undefined-0.02 undefined
20220.29 undefined0.01 undefined0.02 undefined
20210.28 undefined0.03 undefined0.02 undefined
20200.31 undefined0.11 undefined0.06 undefined
20190.27 undefined0.1 undefined0.06 undefined
20180.22 undefined0.06 undefined0.04 undefined
20170.19 undefined0.05 undefined-0.16 undefined
20160.04 undefined-0.03 undefined-0.04 undefined
20150.03 undefined-0.03 undefined-0.02 undefined
20140.05 undefined0.01 undefined-0.01 undefined
20130.03 undefined-0.03 undefined-0.07 undefined
20120.14 undefined-0.18 undefined-0.33 undefined
20110.06 undefined-0.35 undefined-0.36 undefined
20100.06 undefined-0.87 undefined-1.87 undefined
20090.09 undefined-2.36 undefined-2.74 undefined
20080.08 undefined-2.75 undefined-2.85 undefined
20070.08 undefined-2.64 undefined-3.87 undefined
20060.01 undefined-2.02 undefined-2.13 undefined
20050.05 undefined-2.3 undefined-2.24 undefined
20040.12 undefined-2.27 undefined-2.2 undefined

Pharming Group business model

Pharming Group NV was founded in 1988 and is headquartered in the Netherlands. The company specializes in the development and marketing of medical products for the treatment of rare diseases. Its business model is based on the discovery and development of recombinant proteins. These proteins are produced using genetic engineering techniques and serve as the foundation for the development of therapeutic products in various areas. The main focus of Pharming Group NV is the manufacturing and marketing of biopharmaceuticals. The company has a wide range of products used in the treatment of rare diseases, including C1-esterase inhibitor preparations used for acute attacks in hereditary angioedema. Another important product of Pharming Group NV is recombinant human lysozyme. It is used in the treatment of cystic fibrosis and has shown promising results as a therapeutic approach. Pharming Group NV also collaborates closely with various research and development organizations to develop new products and expand knowledge in the medical industry. The company has experienced impressive growth in recent years. In 2019, Pharming Group NV achieved a revenue of 149 million euros. A significant portion of this revenue was generated through the sale of C1-esterase inhibitor preparations. Pharming Group NV has also made a name for itself in the international market. The company has branches in the USA and Europe and works closely with international regulatory authorities to ensure smooth approval and marketing of its products. Overall, Pharming Group NV has a promising future as it continues to invest in research, development, and expansion of its product portfolio. By focusing on the development of products for the treatment of rare diseases, Pharming Group NV positions itself as a leading company in the medical industry and contributes to improving the lives of people worldwide. Pharming Group is one of the most popular companies on Eulerpool.com.

Pharming Group SWOT Analysis

Strengths

1. Established track record: Pharming Group NV has a strong history of developing and launching successful pharmaceutical products.

2. Innovative research and development: The company invests heavily in R&D, which allows it to stay at the forefront of advanced medical therapies.

3. Strong intellectual property portfolio: Pharming Group NV holds numerous patents for its products, providing a competitive advantage in the market.

Weaknesses

1. Dependence on limited product portfolio: The company heavily relies on a few key products for its revenue, leaving it vulnerable to market fluctuations.

2. Regulatory challenges: The pharmaceutical industry is heavily regulated, and any changes in regulations or delays in obtaining approvals can impact Pharming Group NV's operations.

3. High research and development costs: While investment in R&D is a strength, it also presents a financial burden for the company, potentially affecting profitability.

Opportunities

1. Market expansion: Pharming Group NV can explore new markets and regions to increase its customer base and revenue streams.

2. Collaborations and partnerships: Forming strategic alliances can help the company access new technologies, expertise, and distribution channels.

3. Growing demand for rare disease treatments: As the awareness and need for rare disease therapeutics increase, Pharming Group NV can leverage its expertise in this area.

Threats

1. Intense competition: The pharmaceutical industry is highly competitive, with established players and new entrants vying for market share.

2. Pricing pressures: Pricing pressures from governments, payers, and insurers can impact the profitability of Pharming Group NV's products.

3. Intellectual property challenges: The risk of patent infringements or challenges to existing patents can threaten Pharming Group NV's market exclusivity.

Pharming Group Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Pharming Group historical P/E ratio, EBIT, and P/S ratio.

Pharming Group shares outstanding

The number of shares was Pharming Group in 2023 — This indicates how many shares 657.021 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Pharming Group earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Pharming Group's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Pharming Group’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Pharming Group's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Pharming Group Stock splits

In Pharming Group's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Pharming Group.

Pharming Group latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20240.01 -0  (-124.39 %)2024 Q2
3/31/20240.01 -0.02  (-363.89 %)2024 Q1
12/31/20230.01 -0  (-138.84 %)2023 Q4
9/30/2023-0.03 0.01  (118.66 %)2023 Q3
6/30/2023-0.01 0  (100 %)2023 Q2
3/31/2023-0.01 -0.02  (-153.73 %)2023 Q1
12/31/20220.01 -0.02  (-427.87 %)2022 Q4
9/30/20220 0.01  (0 %)2022 Q3
6/30/20220.01 0  (-61.54 %)2022 Q2
12/31/20210 0  (0 %)2021 Q4
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the Pharming Group stock

Eulerpool World ESG Rating (EESG©)

60/ 100

🌱 Environment

28

👫 Social

80

🏛️ Governance

73

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Pharming Group list of shareholders

%
Name
Stocks
Change
Date
2.95241 % RTW Investments L.P.20,027,808-18,468,5831/18/2024
2.94580 % Acadian Asset Management LLC19,982,95919,982,9599/1/2022
2.81671 % BlackRock Institutional Trust Company, N.A.19,107,282401,4132/14/2024
1.46718 % DWS Investment GmbH9,952,7067,556,7972/6/2024
1.41719 % Victory Capital Management Inc.9,613,5341,071,77312/31/2023
1.39951 % JP Morgan Asset Management9,493,622-604,0312/14/2023
1.25963 % de Vries (Sijmen)8,544,736403,3533/15/2024
1.24389 % Dimensional Fund Advisors, L.P.8,437,96203/31/2024
0.85739 % Bank of America Corp5,816,1231,313,9782/15/2023
0.84819 % Norges Bank Investment Management (NBIM)5,753,7171,149,99912/31/2023
1
2
3
4
5
...
10

Pharming Group Executives and Management Board

Dr. Sijmen de Vries64
Pharming Group Chief Executive Officer, Executive Director
Compensation 2.4 M
Mr. Paul Sekhri65
Pharming Group Non-Executive Independent Chairman of the Board (since 2015)
Compensation 114,000
Mr. Leonard Kruimer65
Pharming Group Non-Executive Independent Director
Compensation 89,000
Ms. Jabine van der Meijs57
Pharming Group Non-Executive Independent Director
Compensation 89,000
Ms. Deborah Jorn65
Pharming Group Non-Executive Independent Vice Chairman of the Board (since 2019)
Compensation 87,000
1
2
3

Pharming Group Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Sanofi Stock
Sanofi
SupplierCustomer0,950,720,480,29-0,16-0,57
Kamada Stock
Kamada
SupplierCustomer-0,300,580,450,18-0,090,42
Omnicom Stock
Omnicom
SupplierCustomer-0,560,130,120,410,18-0,39
Open Orphan Stock
Open Orphan
SupplierCustomer-0,770,29-0,090,110,700,29
Novartis Stock
Novartis
SupplierCustomer-0,870,13-0,140,040,520,13
1

Most common questions regarding Pharming Group

What values and corporate philosophy does Pharming Group represent?

Pharming Group NV represents values of innovation, collaboration, and patient-centricity. As a leading biotech company, Pharming is committed to developing innovative therapies for patients with unmet medical needs. They prioritize collaboration by partnering with research institutions, healthcare professionals, and patient organizations to advance scientific knowledge. Pharming's corporate philosophy revolves around improving the quality of life for patients through the development and commercialization of novel therapies. Their dedication to scientific excellence, integrity, and global outreach enables them to provide effective and life-changing therapies for patients around the world.

In which countries and regions is Pharming Group primarily present?

Pharming Group NV is primarily present in several countries and regions worldwide. The company has a strong presence in the United States, where it operates its North American headquarters. Additionally, Pharming Group NV has a significant presence in Europe, with offices and distribution networks in various countries such as the Netherlands, Germany, France, Italy, and the United Kingdom. Furthermore, the company has expanded its reach into Asia, particularly in important markets like Japan and South Korea. With its global presence, Pharming Group NV is able to effectively deliver its innovative biopharmaceutical products and therapies to patients across different continents.

What significant milestones has the company Pharming Group achieved?

Pharming Group NV has achieved several significant milestones. Notably, the company received approval for its lead product, Ruconest, by regulatory authorities in the United States and Europe. This approval allows Pharming Group NV to market Ruconest for the treatment of acute hereditary angioedema attacks, enhancing the company's market presence. Additionally, Pharming Group NV has successfully expanded Ruconest's sales and commercial footprint, securing distribution agreements in various countries. The company's consistent efforts in research and development have resulted in the exploration of new therapeutic areas, such as Pompe disease. Pharming Group NV's commitment to innovation and attaining regulatory approvals has paved the way for its growth and success in the biopharmaceutical industry.

What is the history and background of the company Pharming Group?

Pharming Group NV is a biopharmaceutical company with a rich history and remarkable background. The company was established in 1988, headquartered in the Netherlands. Pharming focuses on the development and commercialization of innovative protein replacement therapies and precision medicines utilizing its proprietary technology platform. The company is renowned for its pioneering work in the field of recombinant human plasma proteins, particularly Recombinant Human C1 Inhibitor (rhC1INH). Pharming Group NV has successfully developed and marketed these life-saving treatments for hereditary angioedema (HAE) and acquired angioedema (AAE), significantly improving the lives of patients worldwide. With an impressive track record of scientific expertise and substantial market presence, Pharming Group NV continues to be a leading player in the biopharmaceutical industry.

Who are the main competitors of Pharming Group in the market?

The main competitors of Pharming Group NV in the market include Biocryst Pharmaceuticals, CSL Behring, Grifols, and Takeda Pharmaceutical Company Limited.

In which industries is Pharming Group primarily active?

Pharming Group NV is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Pharming Group?

Pharming Group NV operates under a unique business model. The company specializes in the development and commercialization of innovative biotherapeutics using its proprietary technology platform, known as the recombinant human C1 esterase inhibitor (rhC1INH). This technology allows Pharming Group to produce and deliver recombinant human proteins, addressing unmet medical needs in diseases such as hereditary angioedema (HAE) and lysosomal storage disorders. By leveraging their scientific expertise and strategic partnerships, Pharming Group NV aims to improve the quality of life for patients and create value for their stakeholders.

What is the P/E ratio of Pharming Group 2024?

The Pharming Group P/E ratio is -113.7.

What is the P/S ratio of Pharming Group 2024?

The Pharming Group P/S ratio is 1.56.

What is the AlleAktien quality score of Pharming Group?

The AlleAktien quality score for Pharming Group is 4/10.

What is the revenue of Pharming Group 2024?

The expected Pharming Group revenue is 305.92 M USD.

How high is the profit of Pharming Group 2024?

The expected Pharming Group profit is -4.19 M USD.

What is the business model of Pharming Group

The Pharming Group NV is a biopharmaceutical company specialized in the development of innovative therapies for rare genetic diseases. The company is based in Leiden, Netherlands and is listed on the Euronext Amsterdam exchange. Pharming's business model is based on the research and development of biopharmaceuticals for the treatment of rare genetic diseases. The company focuses particularly on rare immune system disorders, including Hereditary Angioedema (HAE) and Lymphocytic Varicosis (LV). Pharming also conducts clinical trials for the treatment of other rare diseases. Pharming's products include Ruconest, a recombinant C1 esterase inhibitor (rhC1INH) used for the treatment of HAE. Ruconest is Pharming's flagship product and is marketed globally. The company has also developed a biosimilar version of Ruconest, which is produced under the brand name RucON. Pharming also has a pipeline of future products in development, including a recombinant factor VIII for the treatment of Hemophilia A and a recombinant factor IX for the treatment of Hemophilia B. The company is also working on the development of therapies for the treatment of rarer diseases such as Vascular Ehlers-Danlos Syndrome (EDS). Pharming pursues a diversified business model with a focus on research and development, production, and marketing of biopharmaceuticals. The company also operates its own manufacturing facility to ensure the production of biopharmaceuticals. Pharming also follows a strategic acquisition strategy to expand its product pipeline and increase market presence. Pharming's business model is based on a strong research and development pipeline, efficient production, a differentiated product range, and a strong marketing strategy to increase its presence in the markets. Pharming's focus on rare genetic diseases and continuous innovation in the treatment of these diseases make the company an important player in the biopharmaceutical market.

What is the Pharming Group dividend?

Pharming Group pays a dividend of 0 USD distributed over payouts per year.

How often does Pharming Group pay dividends?

The dividend cannot currently be calculated for Pharming Group or the company does not pay out a dividend.

What is the Pharming Group ISIN?

The ISIN of Pharming Group is NL0010391025.

What is the Pharming Group WKN?

The WKN of Pharming Group is A1H65A.

What is the Pharming Group ticker?

The ticker of Pharming Group is PHARM.AS.

How much dividend does Pharming Group pay?

Over the past 12 months, Pharming Group paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pharming Group is expected to pay a dividend of 0 USD.

What is the dividend yield of Pharming Group?

The current dividend yield of Pharming Group is .

When does Pharming Group pay dividends?

Pharming Group pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Pharming Group?

Pharming Group paid dividends every year for the past 0 years.

What is the dividend of Pharming Group?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Pharming Group located?

Pharming Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Pharming Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Pharming Group from 9/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/9/2024.

When did Pharming Group pay the last dividend?

The last dividend was paid out on 9/9/2024.

What was the dividend of Pharming Group in the year 2023?

In the year 2023, Pharming Group distributed 0 USD as dividends.

In which currency does Pharming Group pay out the dividend?

The dividends of Pharming Group are distributed in USD.

All fundamentals about Pharming Group

Our stock analysis for Pharming Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pharming Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.